secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001785530-24-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026
--------------------------------------------------------------------------------

- Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.
- Cash and equivalents $139.2M at March 31, 2024; new $60M loan from K2 HealthVentures ($30M drawn) extends runway through Q1 2026.
- Collaboration revenue from Jazz Pharma fell to $0.7M from $4.5M YoY.
- Planned ASCO 2024 presentation of WTX-124 combination dose-escalation data; Q2 interim data for WTX-330 monotherapy.
- Preclinical advances: WTX-518 and WTX-712 show tumor regressions in mouse models; IL-10 for IBD presented at AAI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/0001785530-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/howl-20240503.htm
  HTML page:      https://secwatch.observer/filing/0001785530-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer